Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

AZ says target of $45bn sales by 2023 still achievable

The underlying picture is strong, however, with new medicines like Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma growing 19% in the first nine months of ... Lynparza (olaparib) for ovarian and breast cancer more

Latest news

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    All three drugs are already approved for maintenance in relapsed/refractory ovarian cancer, but first-line approval would allow Lynparza to move up the treatment pathway ahead of its competitors. ... nivolumab) in ‘all-comer’first-line ovarian cancer,

  • Artificial intelligence in healthcare Artificial intelligence in healthcare

    AI is already being used to identify women whose Twitter posts indicate may have increased risk of developing ovarian and cervical cancer, and earlier this year the UK launched a project ... The aim is to spot at least 50, 000 cases of prostate, ovarian,

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    The highlights of the targeted cancer therapy track include the SOLO-1 trial of AstraZeneca’s PARP inhibitor Lynparza (olaparib) as a maintenance treatment for BRCA1/2-mutated ovarian cancer, and ... VEGF/FGF/PDGF inhibitor will give an update on

  • BMS finds a new immunotherapy partner with $12m Compugen deal BMS finds a new immunotherapy partner with $12m Compugen deal

    The Israel-based company’s lead candidate COM701 is a first-in-class cancer immunotherapy (IO) antibody targeting PVRIG, a novel immune checkpoint identified by Compugen’s computational discovery capabilities. ... Compugen says COM701 preclinical

  • China’s Innovent to start US trials of anti-CD47 cancer drug China’s Innovent to start US trials of anti-CD47 cancer drug

    Some cancer cells express CD47 at very high levels and this seems to correlate with poor survival. ... lymphoma and ovarian cancer.

More from news
Approximately 35 fully matching, plus 149 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There are two stand- out good news stories for AZ in 2018 – the growth of its cancer medicines portfolio and industry-leading sales expansion in China. ... Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... tumours. Researchers are also investigating whether preventive vaccines could be deployed in people with high-risk cancer

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics